RAGE suppresses ABCG1-mediated macrophage cholesterol efflux in diabetes

Diabetes

Volumn 64, Issue 12, 2015, Pages 4046-4060

  Daffu, Gurdip ^a   Shen, Xiaoping ^a   Senatus, Laura ^a   Thiagarajan, Devi ^a   Abedini, Andisheh ^a   Del Pozo, Carmen Hurtado ^a   Rosario, Rosa ^a   Song, Fei ^a   Friedman, Richard A ^b   Ramasamy, Ravichandran ^a   Schmidt, Ann Marie ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; ADVANCED GLYCATION END PRODUCT RECEPTOR; APOLIPOPROTEIN A1; CHLORDANE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LIVER X RECEPTOR; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL; ABC TRANSPORTER; ABCG1 PROTEIN, HUMAN; ABCG1 PROTEIN, MOUSE; ADVANCED GLYCATION END PRODUCT; AGER PROTEIN, HUMAN; AGER PROTEIN, MOUSE; LIGAND; LIPOPROTEIN; RECOMBINANT PROTEIN;

ANIMAL CELL; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; FECES; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; LIVER; LOW DENSITY LIPOPROTEIN RECEPTOR KO MOUSE; MACROPHAGE; MALE; MICRODISSECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA TRANSCRIPTION; TRIACYLGLYCEROL BLOOD LEVEL; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA; BLOOD; CELL CULTURE; CELL LINE; CHEMISTRY; CYTOLOGY; DIABETIC ANGIOPATHY; GENETICS; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PROMOTER REGION; TRANSPORT AT THE CELLULAR LEVEL;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; AORTA; ATP BINDING CASSETTE TRANSPORTER 1; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY G, MEMBER 1; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL LINE; CELLS, CULTURED; CHOLESTEROL; DIABETIC ANGIOPATHIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIGANDS; LIPOPROTEINS; MACROPHAGES; MALE; MICE, KNOCKOUT; PLAQUE, ATHEROSCLEROTIC; PPAR GAMMA; PROMOTER REGIONS, GENETIC; RECOMBINANT PROTEINS;

EID: 84958210369     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-0575     Document Type: Article

References (52)

1. Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003; 46:760-765
2. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1987;30:123-131
3. Burke AP, Kolodgie FD, Zieske A, et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol 2004;24:1266-1271
4. Shiu SW, Zhou H, Wong Y, Tan KC. Endothelial lipase and reverse cholesterol transport in type 2 diabetes mellitus. J Diabetes Investig 2010;1:111-116
5. Zhou H, Shiu SW, Wong Y, Tan KC. Impaired serum capacity to induce cholesterol efflux is associated with endothelial dysfunction in type 2 diabetes mellitus. Diab Vasc Dis Res 2009;6:238-243
6. de Boer JF, Annema W, Schreurs M, et al. Type I diabetes mellitus decreases in vivo macrophage-to-feces reverse cholesterol transport despite increased biliary sterol secretion in mice. J Lipid Res 2012;53:348-357
7. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011;364: 127-135
8. Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 2014;371:2383-2393
9. Mauldin JP, Nagelin MH, Wojcik AJ, et al. Reduced expression of ATP-binding cassette transporter G1 increases cholesterol accumulation in macrophages of patients with type 2 diabetes mellitus. Circulation 2008;117: 2785-2792
10. Patel DC, Albrecht C, Pavitt D, et al. Type 2 diabetes is associated with reduced ATP-binding cassette transporter A1 gene expression, protein and function. PLoS One 2011;6:e22142
11. Cipollone F, Iezzi A, Fazia M, et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003;108: 1070-1077
12. Bu DX, Rai V, Shen X, et al. Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic apoE-null mice. Circ Res 2010;106: 1040-1051
13. Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998;4:1025-1031
14. Morris-Rosenfeld S, Blessing E, Preusch MR, et al. Deletion of bone marrow-derived receptor for advanced glycation end products inhibits atherosclerotic plaque progression. Eur J Clin Invest 2011;41:1164-1171
15. Wendt T, Harja E, Bucciarelli L, et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 2006;185:70-77
16. Weischenfeldt J, Porse B. Bone marrow-derived macrophages (BMM): isolation and applications. CSH Protoc 2008;2008:pdb prot5080
17. Zhang X, Goncalves R, Mosser DM. The isolation and characterization of murine macrophages. Curr Protoc Immunol 2008;Chapter 14:Unit 14.1
18. Uehara Y, Miura S, von Eckardstein A, et al. Unsaturated fatty acids suppress the expression of the ATP-binding cassette transporter G1 (ABCG1) and ABCA1 genes via an LXR/RXR responsive element. Atherosclerosis 2007; 191:11-21
19. Matys V, Kel-Margoulis OV, Fricke E, et al. TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res 2006;34:D108-D110
20. Kel-Margoulis OV, Tchekmenev D, Kel AE, et al. Composition-sensitive analysis of the human genome for regulatory signals. In Silico Biol 2003;3:145-171
21. Okuno M, Arimoto E, Ikenobu Y, Nishihara T, Imagawa M. Dual DNA-binding specificity of peroxisome-proliferator-activated receptor gamma controlled by heterodimer formation with retinoid X receptor alpha. Biochem J 2001;353:193-198
22. Lemberger T, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol 1996;12:335-363
23. Srivastava S, Vladykovskaya E, Barski OA, et al. Aldose reductase protects against early atherosclerotic lesion formation in apolipoprotein E-null mice. Circ Res 2009;105:793-802
24. Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, Rader DJ. Over-expression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 2003;108:661-663
25. Fligner MA, Killeen TJ. Distribution-free two sample tests of scale. J Am Stat Assoc 1976;75:315-319
26. Welch BL. On the comparison of several mean values: an alternative approach. Biometrika 1951;38:330-336
27. Westfall PH. Multiple testing of general contrasts using logical constraints and conditions. J Am Stat Assoc 1997;92:299-306
28. Westfall PH, Tobias RD. Multiple testing of general contrasts: truncated closure and the extended Shaffer-Royen method. J Am Stat Assoc 2007;102: 487-494
29. Hothorn T, Bretz F, Westfall P. Simultaneous inference in general parametric models. Biom J 2008;50:346-363
30. Zeiles A. Econometric computing with HC and HAC covariance matrix estimators. J Stat Softw 2006;11:1-17
31. Zeileis A. Object-oriented computation of sandwich estimators. J Stat Softw 2006;16:1-16
32. Mauldin JP, Srinivasan S, Mulya A, et al. Reduction in ABCG1 in type 2 diabetic mice increases macrophage foam cell formation. J Biol Chem 2006;281: 21216-21224
33. Tang C, Kanter JE, Bornfeldt KE, Leboeuf RC, Oram JF. Diabetes reduces the cholesterol exporter ABCA1 in mouse macrophages and kidneys. J Lipid Res 2010;51:1719-1728
34. Kislinger T, Fu C, Huber B, et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999; 274:31740-31749
35. Boisvert WA, Black AS, Curtiss LK. ApoA1 reduces free cholesterol accumulation in atherosclerotic lesions of apoE-deficient mice transplanted with apoE-expressing macrophages. Arterioscler Thromb Vasc Biol 1999;19: 525-530
36. Tontonoz P, Mangelsdorf DJ. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 2003;17:985-993
37. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001;7:48-52
38. Chawla A, Boisvert WA, Lee CH, et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001;7:161-171
39. Moore KJ, Rosen ED, Fitzgerald ML, et al. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med 2001;7:41-47
40. Yang Q, Chen C, Wu S, Zhang Y, Mao X, Wang W. Advanced glycation end products downregulates peroxisome proliferator-activated receptor g expression in cultured rabbit chondrocyte through MAPK pathway. Eur J Pharmacol 2010; 649:108-114
41. Merat S, Casanada F, Sutphin M, Palinski W, Reaven PD. Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-rich diet. Arterioscler Thromb Vasc Biol 1999;19:1223-1230
42. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW. The myeloperoxidase system of human phagocytes generates Nepsilon-(carbox-ymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999;104:103-113
43. Machado AP, Pinto RS, Moysés ZP, Nakandakare ER, Quintão EC, Passarelli M. Aminoguanidine and metformin prevent the reduced rate of HDL-mediated cell cholesterol efflux induced by formation of advanced glycation end products. Int J Biochem Cell Biol 2006;38:392-403
44. Yang Y, Zhao LH, Huang B, et al. Pioglitazone, a PPARg agonist, inhibits growth and invasion of human hepatocellular carcinoma via blockade of the rage signaling. Mol Carcinog. 12 October 2014 [Epub ahead of print]. DOI: 10.1002/mc.22231
45. Liang YJ, Jian JH, Chen CY, Hsu CY, Shih CY, Leu JG. L-165,041, trogli-tazone and their combination treatment to attenuate high glucose-induced receptor for advanced glycation end products (RAGE) expression. Eur J Pharmacol 2013;715:33-38
46. Ozasa H, Ayaori M, Iizuka M, et al. Pioglitazone enhances cholesterol efflux from macrophages by increasing ABCA1/ABCG1 expressions via PPARg/LXRa pathway: findings from in vitro and ex vivo studies. Atherosclerosis 2011;219:141-150
47. Li AC, Binder CJ, Gutierrez A, et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest 2004;114:1564-1576
48. Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 2009;50(Suppl.):S189-S194
49. Tuteja S, Rader DJ. High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm. Clin Pharmacol Ther 2014;96: 48-56
50. Hayashi T, Kotani H, Yamaguchi T, et al. Endothelial cellular senescence is inhibited by liver X receptor activation with an additional mechanism for its atheroprotection in diabetes. Proc Natl Acad Sci U S A 2014;111:1168-1173
51. Neeli H, Gadi R, Rader DJ. Managing diabetic dyslipidemia: beyond statin therapy. Curr Diab Rep 2009;9:11-17
52. Stegman B, Puri R, Cho L, et al. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care 2014;37:3114-3120